A Food and Drug Administration advisory panelist who voted against keeping the controversial drug Avandia on the market had been a paid speaker for the maker of a rival diabetes drug, The Wall Street Journal reports.
Abraham Thomas, head of the endocrinology and diabetes division at Henry Ford Hospital in Detroit, had worked as a speaker for Takeda Pharmaceutical Co. between September 2007 and September 2008, earning $2,000 to $3,000.
Takeda makes the drug Actos, which has raised fewer safety concerns than Avandia. Sales of Actos have been boosted by Avandia’s woes.
Tuesday, panelist David Capuzzi of Philadelphia confirmed to the Journal that he had been a paid speaker for Avandia’s maker, GlaxoSmithKline. Capuzzi was one of only three panelists who voted to keep the diabetes drug on the market without new warnings or restrictions.
A 2007 study published in The New England Journal of Medicine first prompted scrutiny of Avandia when it claimed the drug could increase the risk of heart attacks by 40 percent. Some diabetes patients and doctors have asked the FDA to keep the drug on the market because of its effectiveness.
Last week’s advisory panel voted 20-12 to keep Avandia on the market, though 17 of the panelists who backed the drug wanted additional warnings about heart risks or tighter prescribing restrictions.
Dr. Thomas said he informed the FDA about his financial ties to the drug company.
“I do not remember there being any issue brought up about the Takeda speakers bureau” by the FDA, he said in a statement. “This may be due to the fact this was several years ago.” The FDA did not respond immediately to questions about Thomas.
“If any member of the advisory committee is found to have a conflict of interest, FDA can consider that information as we make our final decision on the status of the drug,” the FDA said in a statement Tuesday.
Related Links:
Panelist Who Backed Avandia Had Financial Ties to Glaxo
Health Professionals Urge Patients Not to Abandon Avandia Pills


